4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine

Cambridge, UK, 21 March 2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, today announces that the Company’s client, Helix Nanotechnologies Inc. (“HelixNano”) has received HREC approval to progress into a Phase I clinical trial in Australia with HN-0001, an mRNA vaccine generated from 4basebio’s synthetic DNA, opDNA™.

4basebio will continue to support HelixNano with the manufacture of GMP synthetic DNA planned for later in 2024.

Dr Amy Walker, VP of Research and Business Development at the Company, commented: "It’s been a pleasure to work with such an innovative company on their journey to the clinic and we are delighted to see an mRNA vaccine manufactured using 4basebio DNA progressing into patients; this represents another significant milestone for the company.”

“4basebio has several clients requiring GMP grade DNA and progressing towards clinical trials; we are of course very pleased to be supporting our clients in their clinical programs.”

Dr Marianna Keaveney, Director of Clinical Product Development at HelixNano, commented: “It's an incredible milestone for HelixNano to secure approval for our first clinical trial, and we would not have been able to develop this drug product without the commitment of the 4basebio team. We look forward to continuing our work together.”